Discover SPRAVATO®
SPRAVATO® is the first FDA-approved nasal spray specifically for adults with treatment-resistant depression. It may offer a new option if two or more antidepressants of adequate dose and duration have not provided relief.
A Different Approach to Treatment-Resistant Depression
If treatment-resistant depression is a challenge, SPRAVATO® offers a new option.
Adults who have tried two or more antidepressants at adequate doses and durations without relief may be experiencing treatment-resistant depression. SPRAVATO® works differently from conventional medications.
While most oral antidepressants help by increasing neurotransmitters such as serotonin, norepinephrine, and dopamine in areas of the brain that affect mood, SPRAVATO® targets the NMDA receptor, providing a unique mechanism of action. The exact way SPRAVATO® works is not yet fully understood.
“Allison’s son tried many oral antidepressants without relief. Now, because of SPRAVATO®, Allison’s son is starting to feel like himself again.”
Clinical Effectiveness of SPRAVATO®
SPRAVATO® has demonstrated effectiveness for adults with treatment-resistant depression when used alongside an oral antidepressant.
In a short-term clinical study, adults who received SPRAVATO® with an oral antidepressant showed a greater reduction in depressive symptoms after four weeks compared to those who received a placebo with an oral antidepressant.
Long-term studies over 16 weeks revealed that patients who continued SPRAVATO® treatment were less likely to experience a return of depressive symptoms than those who discontinued therapy.
*Includes adults with major depressive disorder who did not respond adequately to at least two different antidepressants of sufficient dose and duration in the current episode.
SPRAVATO® for Major Depressive Disorder with Suicidal Thoughts
SPRAVATO® may also be used for adults with major depressive disorder who experience active suicidal thoughts or behaviors.
Clinical studies show that patients taking SPRAVATO® alongside an oral antidepressant experienced a noticeable reduction in depressive symptoms within 24 hours, with continued improvement over four weeks of treatment. Following the treatment plan created with your healthcare provider is essential, as not all patients respond to SPRAVATO®.
SPRAVATO® is not proven to prevent suicide or reduce suicidal thoughts or actions and is not a substitute for hospitalization if deemed necessary.
It is not intended to relieve pain or serve as an anesthetic, and its safety and effectiveness in children are unknown.
Please review the Important Safety Information, full Prescribing Information, and Medication Guide for SPRAVATO®, and discuss any questions with your healthcare provider.
SPRAVATO® Side Effects
SPRAVATO® may cause serious side effects, including:
- Sedation or sleepiness
- Feeling disconnected from yourself, your thoughts, or your surroundings (dissociation)
- Risk of abuse or misuse
- Increased suicidal thoughts or behaviors
- Elevated blood pressure
- Difficulty thinking clearly
- Bladder problems
These are not all possible side effects. For complete safety information, please review the full prescribing information and Medication Guide for SPRAVATO®.
If you experience side effects, contact your healthcare provider for guidance. Side effects can also be reported to the FDA at 1-800-FDA-1088.
Serious Side Effects and Precautions
SPRAVATO® may cause serious side effects. Key precautions include:
- Increased Blood Pressure: Blood pressure may rise temporarily for up to four hours after a dose. Your healthcare provider will monitor blood pressure before and for at least two hours after treatment. Seek immediate care for chest pain, shortness of breath, severe headache, vision changes, or seizures.
- Cognitive Effects: Report any problems with thinking clearly or memory issues to your healthcare provider.
- Bladder Issues: Inform your provider if you experience difficulty urinating, frequent urges, pain during urination, or frequent nighttime urination.
Not all patients respond to SPRAVATO®. While studies show a reduction in depressive symptoms within 24 hours when combined with an oral antidepressant, ongoing treatment and adherence to your healthcare provider’s plan are essential.
SPRAVATO® is not proven to prevent suicide or replace hospitalization if needed. It is also not approved as an anesthetic, and its safety in children has not been established.
Common Side Effects of SPRAVATO®
When used with an oral antidepressant, SPRAVATO® may cause some common side effects, including:
- Feeling disconnected from yourself, your thoughts, or your surroundings
- Dizziness or spinning sensations
- Nausea or vomiting
- Sleepiness or lack of energy
- Numbness or decreased sensitivity
- Anxiety or elevated mood
- Temporary increases in blood pressure
- Feeling unusually happy or intoxicated
These effects are generally temporary, but any persistent or concerning symptoms should be discussed with your healthcare provider.
Discuss SPRAVATO® With Your Healthcare Provider
SPRAVATO® may not be suitable for everyone. Before starting treatment, review your full medical history with your healthcare provider, including if you:
- Have a history of prescription or street drug abuse
- Struggle with alcohol use
- Are pregnant, planning pregnancy, breastfeeding, or planning to breastfeed
- Take prescription or over-the-counter medications, vitamins, or herbal supplements
Your First Treatment Center Visit
At your first consultation with a certified SPRAVATO® treatment center, our team will:
- Review the medical information provided by your healthcare provider
- Conduct an assessment to determine if SPRAVATO® is appropriate
- Verify insurance coverage and eligibility
If recommended, a personalized treatment plan will be created, and you will be enrolled in the SPRAVATO® REMS Program to ensure safety throughout treatment.
SPRAVATO® is covered by most insurance plans, with additional support programs available to help manage costs.